(331 days)
Not Found
Not Found
No
The device description and performance studies focus on traditional immunoassay methods and do not mention any AI or ML components.
No.
This device is an in-vitro diagnostic test used for the detection of drugs in urine, which assists in diagnosing or screening for drug abuse, rather than providing therapy or treatment.
Yes
The "Intended Use / Indications for Use" section explicitly states "The QuickScreen Barbiturates Test is a qualitative in-vitro diagnostic screen..." and "Measurements obtained by this device are used in the diagnosis and treatment of drug abuse." These statements confirm its diagnostic purpose.
No
The device is described as an immunoassay for the qualitative detection of substances in urine, which is a physical test requiring a physical test strip or kit, not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicitly stated in the Intended Use: Several of the descriptions explicitly state "in-vitro diagnostic screen" or "An invitro diagnostic test".
- Analyzes a biological sample (urine): The device is designed to detect substances in urine, which is a biological sample.
- Used to provide information about a medical condition (drug abuse): The intended use mentions assisting in the prevention of drug abuse and that measurements are used in the diagnosis and treatment of drug abuse.
- Intended for professional use: This indicates it's a medical device used in a healthcare or laboratory setting.
N/A
Intended Use / Indications for Use
The QuickScreen™ Barbiturates Test is a rapid, qualitative immunoassay for the detection of Barbiturates in urine. The cutoff concentration for this test is 300 ngdomly This assay is intended for professional use.
QuickScreen Multi Drug Screening Test is a rapid, qualitative immunoassay for the detection of the target drugs/drug metabolites in urine. This assay is intended to assist in the prevention of drug abuse.
The QuickScreen Barbiturates Test is a qualitative in-vitro diagnostic screen that provides a preliminary result for the detection/presence of Barbiturates in urine. Tests for barbiturates cannot distinguish between abused drugs and certain prescribed medications. The cut-off concentration will be 300 ng/ml (secobarbital). It is intended for professional use only.
This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.
An invitro diagnostic test for the qualitative detection of amphetamine, cocaine, methamphetamine, opiates, PCP, Barbiturates, benzodiazepines, methadone and THC in urine. Tests for prescription drugs cannot distinguish between abused drugs and certain prescribed medications. Measurements obtained by this device are used in the diagnosis and treatment of drug abuse. It is intended for professional use only.
This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.
Product codes (comma separated list FDA assigned to the subject device)
DIS
Device Description
Immunoassay for the qualitative detection of Barbiturates in urine.
The QuickScreen™ Barbiturates Test, like many commercially available barbiturate screening test kits, qualitatively measures the presence of Barbiturates by visual color sandwich one step immunoassay technology. These devices rely on the hoss immunochemical sandwich assay principle of recognition of specific of specific antibody / target analyte / antibody / complexes.
Immunoassay for the qualitative detection, Amphetamine, THC, Cocaine, PCP, Barbiturates, Benzodiazepines, Methadone, Opiates and Methamphetamine in urine.
The QuickScreen Multi Drug Screening Test, like many commercially available drug screening test kits, qualitatively measures the presence of target drugs or their metabolites by visual color sandwich one step immunoassay technology. All of the above devices rely on the basic immunochemical sandwich assay principle of recognition of specific antibody / target drug / antibody / complexes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Urine
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Professional use.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
The product performance characteristics of the QuickScreen™ Barbiturates Test were evaluated in a clinical sample correlation study and a blind labeled spiked study.
The product performance characteristics of the QuickScreen Multi Drug Screening Test were evaluated in a clinical sample correlation study and a blind labeled spiked study. Correlation studies, using clinical specimens, produced a >98% correlation when compared to the Behring EMIT II (Cupertino, CA 95014) and GC/MS methodology. Clinical studies, performed at two independent laboratories, were also performed. In them the Phamatech QuickScreen™ exhibited excellent overall accuracy (>97%) in the hands of professional users.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The results of these studies demonstrate the QuickScreen™ Barbiturates Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of Barbiturates in urine. Laboratory studies, using clinical specimens, produced a 97.9% correlation when compared to the prodicated devices.
The results of these studies demonstrate the Phamatech QuickScreen Multi Drug Screening Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of the stated target drugs in urine. Correlation studies, using clinical specimens, produced a >98% correlation when compared to the Behring EMIT II (Cupertino, CA 95014) and GC/MS methodology. Clinical studies, performed at two independent laboratories, were also performed. In them the Phamatech QuickScreen™ exhibited excellent overall accuracy (>97%) in the hands of professional users.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
97.9% correlation (Barbiturates Test)
98% correlation (Multi Drug Screening Test)
97% overall accuracy (Multi Drug Screening Test)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3150 Barbiturate test system.
(a)
Identification. A barbiturate test system is a device intended to measure barbiturates, a class of hypnotic and sedative drugs, in serum, urine, and gastric contents. Measurements obtained by this device are used in the diagnosis and treatment of barbiturate use or overdose and in monitoring levels of barbiturate to ensure appropriate therapy.(b)
Classification. Class II (special controls). A barbiturate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
510 (k) SUMMARY AS REQUIRED BY SECTION 807.92(C)
ldentification: QuickScreen™ Barbiturates Test: Models 9019, 9018
DEC 07 2007
Description: Immunoassay for the qualitative detection of Barbiturates in urine
Name Of Manufacturer:
Phamatech 10151 Barnes Canyon Road San Diego, California 92121, USA
Intended Use: The QuickScreen™ Barbiturates Test is a rapid, qualitative immunoassay for the detection of Barbiturates in urine. The cutoff concentration for this test is 300 ngdomly This assay is intended for professional use.
Technology: The QuickScreen™ Barbiturates Test, like many commercially available barbiturate screening test kits, qualitatively measures the presence of Barbiturates by visual color sandwich one step immunoassay technology. Examples of such predicated evices include the ABMC RapidOne BZD test (Kinderhook, NY). These devices rely on the hoss immunochemical sandwich assay principle of recognition of specific of specific antibody / target analyte / antibody / complexes.
The product performance characteristics of the QuickScreen™ Barbiturates Performance: Test were evaluated in a clinical sample correlation study and a blind labeled spiked study. The results of these studies demonstrate the QuickScreen™ Barbiturates Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of Barbiturates in urine. Laboratory studies, using clinical specimens, produced a 97.9% correlation when compared to the prodicated devices.
For the reasons mentioned above, it may be concluded that the Conclusion: Phamatech QuickScreen™ Barbiturates Test is substantially equivalent to a variety of detection tests currently in commercial distribution and is safe in the hands of the professional user.
1
510 (k) SUMMARY AS REQUIRED BY SECTION 807.92(C)
Identification: QuickScreen Multi Drug Screening Test: Model 9317T and 9187Z
Description: Immunoassay for the qualitative detection, Amphetamine, THC, Cocaine, PCP, Barbiturates, Benzodiazepines, Methadone, Opiates and Methamphetamine in urine
Name Of Manufacturer:
Phamatech Inc. 10151 Barnes Canyon Road San Diego, California 92121, USA
Intended Use: QuickScreen Multi Drug Screening Test is a rapid, qualitative immunoassay for the detection of the target drugs/drug metabolites in urine. The cut-off concentrations of this test are as follows:
Amphetamine; 1000 ng/ml Barbiturates: 300 nq/ml Benzodiazepines: 200 na/ml Cocaine; 300 ng/ml Methadone 300 nq/ml Methamphetamine; 1000 ng/ml Opiates: 2000 ng/ml. Phencyclidine (PCP) 25 ng/ml THC: 50 nq/ml
This assay is intended to assist in the prevention of drug abuse
The QuickScreen Multi Drug Screening Test, like many commercially available Technology: drug screening test kits, qualitatively measures the presence of target drugs or their metabolites by visual color sandwich one step immunoassay technology. Examples of such predicate devices include the Phamatech QuickScreen At Home Drug Test and the Phamatech QuickScreen Multi Drug Screening Test. All of the above devices rely on the basic immunochemical sandwich assay principle of recognition of specific antibody / target drug / antibody / complexes.
Performance: The product performance characteristics of the QuickScreen Multi Drug Screening Test were evaluated in a clinical sample correlation study and a blind labeled spiked study. The results of these studies demonstrate the Phamatech QuickScreen Multi Drug Screening Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of the stated target drugs in urine. Correlation studies, using clinical specimens, produced a >98% correlation when compared to the Behring EMIT II (Cupertino, CA 95014) and GC/MS methodology. Clinical studies, performed at two independent laboratories, were also performed. In them the Phamatech QuickScreen™ exhibited excellent overall accuracy (>97%) in the hands of professional users.
Conclusion: For the reasons mentioned above, it may be concluded that the Phamatech QuickScreen Multi Drug Screening Test is substantially equivalent to a variety of detection tests currently in commercial distribution and is safe
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with its wings spread, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle. The logo is black and white.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
DEC 0 7 2007
Phamatech、Inc. c/o Mr. Carl Mongiovi Vice President 10151 Barnes Canyon Road San Diego, CA 92121
Re: K070098
Trade/Device Name: Phamatech QuickScreen™ Barbiturates Test Models 9019, 9018, Phamatech Quick Screen™ Pro Multi Drug Screening Test Model 9317T and 9187Z
Regulation Number: 21 CFR 862.3150 Regulation Name: Barbiturate test system. Regulatory Class: Class II Product Code: DIS Dated: October 30, 2007 Received: November 1, 2007
Dear Mr. Mongiovi:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
3
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely vours,
Jean M. Cooper, M.S., D.v.M.
Yéan M. Cooper, M.S., D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
INDICATIONS FOR USE
Applicant: Phamatech
510 (k) Number (if known): _ K_070098
Device Name: Phamatech QuickScreen™ Barbiturates Test Models 9019 , 9018
Indications for Use:
The QuickScreen Barbiturates Test is a qualitative in-vitro diagnostic screen that provides a preliminary result for the detection/presence of Barbiturates in urine. Tests for barbiturates cannot distinguish between abused drugs and certain prescribed medications. The cut-off concentration will be 300 ng/ml (secobarbital). It is intended for professional use only.
This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.
Prescription Use: × AND/OR (Part 21 CFR 801 Subpart D
Over the Counter Use: (21 CFR 807 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED
Concurrence of the CDRH Office of In Vitro Diagnostic Devices (OIVD)
Sean Cooper
Division Sign-Off
Page 1 of 1
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K070098
14
5
INDICATIONS FOR USE
Applicant: Phamatech
510 (k) Number (if known): K 070098 .
Device Name: Phamatech QuickScreen™ Pro Multi Drug Screening Test Model 9317T
Indications for Use:
An invitro diagnostic test for the qualitative detection of amphetamine, cocaine, methamphetamine, opiates, PCP, Barbiturates, benzodiazepines, methadone and THC in urine. Tests for prescription drugs cannot distinguish between abused drugs and certain prescribed medications. Measurements obtained by this device are used in the diagnosis and treatment of drug abuse. It is intended for professional use only.
| Amphetamine | 1000 ng/ml |
|---|---|
| Cocaine | 300 ng/ml |
| Methamphetamine | 1000 ng/ml |
| Opiates | 2000 ng/ml |
| PCP | 25 ng/ml |
| Barbiturates (Secobarbital) | 300 ng/ml |
| Benzodiazepines | 200 ng/ml |
| Methadone | 300 ng/ml |
| THC | 50 ng/ml |
This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.
Prescription Use: X (Part 21 CFR 801 Subpart D AND/OR Over the Counter Use: (21 CFR 807 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED
Concurrence of the CDRH Office of In Vitro Diagnostic Devices (OIVD)
Olan Cooper
Division Sign-Off
Page 1 of 1
6
INDICATIONS FOR USE
Applicant: Phamatech
510 (k) Number (if known): K 070098
Device Name: Phamatech QuickScreen™ Pro Drug Cup Model 9187Z
Indications for Use:
An invitro diagnostic test for the qualitative detection of amphetamine, cocaine, methamphetamine, opiates, PCP, Barbiturates, benzodiazepines, methadone and THC in urine. Tests for prescription drugs cannot distinguish between abused drugs and certain prescribed medications. Measurements obtained by this device are used in the diagnosis and treatment of drug abuse. It is intended for professional use only.
| Amphetamine | 1000 ng/ml |
|---|---|
| Cocaine | 300 ng/ml |
| Methamphetamine | 1000 ng/ml |
| Opiates | 2000 ng/ml |
| PCP | 25 ng/ml |
| Barbiturates (Secobarbital) | 300 ng/ml |
| Benzodiazepines | 200 ng/ml |
| Methadone | 300 ng/ml |
| THC | 50 ng/ml |
This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.
Prescription Use: X (Part 21 CFR 801 Subpart D
Over the Counter Use: AND/OR (21 CFR 807 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED
Concurrence of the CDRH Office of In Vitro Diagnostic Devices (OIVD)
Alan Cooper
Division Sign-Off
Page 1 of 1
510K K070098